Cargando…

Persistent expression of autoantibodies in SLE patients in remission

A majority of the antibodies expressed by nascent B cells in healthy humans are self-reactive, but most of these antibodies are removed from the repertoire during B cell development. In contrast, untreated systemic lupus erythematosus (SLE) patients fail to remove many of the self-reactive and polyr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yurasov, Sergey, Tiller, Thomas, Tsuiji, Makoto, Velinzon, Klara, Pascual, Virginia, Wardemann, Hedda, Nussenzweig, Michel C.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118096/
https://www.ncbi.nlm.nih.gov/pubmed/16966430
http://dx.doi.org/10.1084/jem.20061446
Descripción
Sumario:A majority of the antibodies expressed by nascent B cells in healthy humans are self-reactive, but most of these antibodies are removed from the repertoire during B cell development. In contrast, untreated systemic lupus erythematosus (SLE) patients fail to remove many of the self-reactive and polyreactive antibodies from the naive repertoire. Here, we report that SLE patients in clinical remission continue to produce elevated numbers of self-reactive and polyreactive antibodies in the mature naive B cell compartment, but the number of B cells expressing these antibodies is lower than in patients with active disease. Our finding that abnormal levels of self-reactive mature naive B cells persist in the majority of patients in clinical remission suggests that early checkpoint abnormalities are an integral feature of SLE.